KPV: Research Background and Overview

KPV is one of the smallest peptides that appears regularly in inflammation research. It is a tripeptide — lysine-proline-valine — and it exists in the literature because it is the tail end of a much larger, much older signaling molecule: alpha-melanocyte-stimulating hormone (α-MSH).

Interest in KPV began with a structural question. α-MSH has well-characterized anti-inflammatory activity, but it also drives pigmentation and binds melanocortin receptors throughout the body. Which part of the molecule carried the anti-inflammatory signal? The answer repeatedly pointed to the C-terminal end. KPV is what remains when that question is taken to its minimum.

This article summarizes what the published literature reports about KPV. Nearly all of that literature is preclinical — cultured cells, rodents and rabbits. It contains no guidance on use.

The molecule

α-MSH is a 13-amino-acid peptide with the sequence SYSMEHFRWGKPV. KPV occupies positions 11–13, which is why it appears in papers as “α-MSH(11–13).” At roughly 342 Da in the free-acid form it is very small by peptide standards.

That origin shapes how KPV has been studied. Three properties recur:

• It separates two activities of the parent hormone. The pigment-inducing and classical receptor-binding activity of α-MSH is associated with the core message sequence (His-Phe-Arg-Trp) nearer the N-terminus. Truncated peptides such as KPV have been reported to retain anti-inflammatory activity while lacking the pigment-inducing activity of the full hormone (Böhm and Luger, 2019).
• Its size makes it a transporter substrate. As a tripeptide, KPV falls within the substrate range of the intestinal di/tripeptide transporter PepT1 — a route unavailable to larger peptides.
• Its analogs are not interchangeable. Many studies use protected or amidated forms (Ac-Lys-Pro-Val-NH₂, H-KPV-NH₂) rather than the free tripeptide, and the D-valine variant Lys-Pro-D-Val also appears. Reported results can differ between them.

Mechanisms described in the literature

NF-κB and MAP kinase signaling

The most consistently reported mechanism is suppression of NF-κB-driven transcription. Working in human intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, Dalmasso et al. (2008) reported that nanomolar concentrations of KPV inhibited activation of NF-κB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion after cytokine stimulation.

Land (2012) examined the same pathway in immortalized human bronchial epithelial cells and proposed a more specific mechanism: KPV inhibited TNFα- and virus-evoked NF-κB signaling in association with its own nuclear import, stabilization of IκBα and suppressed nuclear translocation of p65RelA, with competition assays suggesting interference at the importin-α binding site. That is one cell-line study's proposal, not a consensus.

Melanocortin-receptor-dependent and -independent effects

This is where KPV diverges from its parent molecule, and the distinction matters when reading claims about it.

Getting, Schiöth and Perretti (2003) compared KPV against α-MSH, the core HFRW peptide and receptor-selective agonists in a crystal-induced peritonitis model. KPV reduced leukocyte accumulation, but the effect was not blocked by an MC3/MC4 antagonist, it did not raise macrophage cAMP as the agonist MTII did, and it persisted in mice with a non-functional MC1 receptor. The authors concluded KPV is unlikely to act through melanocortin receptors, proposing instead an interaction with IL-1β function.

Kannengiesser and colleagues (2008) reached a compatible conclusion: in mice carrying a non-functional MC1 receptor, KPV still produced a protective effect during DSS colitis, which the authors described as at least partially independent of MC1R signaling.

Land's bronchial epithelial work draws the contrast explicitly: in that system the anti-inflammatory effect of γ-MSH required MC3R, while the KPV effect did not. The working picture is that KPV acts largely through a receptor-independent intracellular route while other melanocortin fragments act through receptors — two distinct literatures that secondary summaries often blend together.

PepT1 in intestinal epithelium

PepT1 is a di/tripeptide transporter normally expressed in the small intestine and reported to be induced in the colon during inflammatory bowel disease. Dalmasso et al. used radiolabeled [³H]KPV and competition experiments with PepT1 substrates to characterize uptake, concluding that KPV enters intestinal epithelial and immune cells via PepT1 — a mechanism that would concentrate the peptide preferentially where the transporter is upregulated.

Viennois and colleagues (2016) tested that dependency genetically. In a murine model of colitis-associated cancer, KPV reduced tumorigenesis in wild-type mice but produced none of those effects in PepT1-knockout mice.

What preclinical research has examined

Colitis models

Colitis is the most developed KPV literature. Dalmasso et al. reported reduced incidence of DSS- and TNBS-induced colitis in mice with decreased pro-inflammatory cytokine expression, and Kannengiesser et al. reported reduced histological inflammatory infiltrate and colonic myeloperoxidase activity in DSS colitis, with comparable effects in a CD45RB^hi transfer model.

Much of the subsequent work is formulation science rather than new biology. Laroui et al. (2010) loaded KPV into nanoparticles encapsulated in an alginate-chitosan hydrogel and reported comparable protective effects in DSS colitis at a far lower peptide load than free peptide in solution; Xiao et al. (2017) used hyaluronic-acid-functionalized nanoparticles, and Zhao et al. (2022) a mucoadhesive hydrogel for rectal delivery in TNBS colitis. The recurring theme: free KPV is poorly retained and rapidly cleared, and much of the reported efficacy depends on getting it to the tissue.

Wound, mucosal and skin models

Bonfiglio et al. (2006) studied α-MSH(11–13) in a rabbit corneal abrasion model and reported faster re-epithelialization relative to vehicle, with the effect blunted by a nitric oxide synthase inhibitor. Shao et al. (2021) reported anti-inflammatory, antibacterial and repair-associated effects for a KPV-loaded mucoadhesive hydrogel in chemotherapy-induced oral mucositis in rats, and Zhao et al. (2022) incorporated KPV alongside EGF into a layered film dressing in a diabetic mouse wound model. Böhm and Luger (2019) reviewed melanocortin peptides in cutaneous wound healing as candidates for future investigation — a proposed research direction, not an established one.

Antimicrobial activity

The antimicrobial literature is real but mixed. Cutuli et al. (2000) reported that α-MSH and its C-terminal tripeptide inhibited Staphylococcus aureus colony formation and reduced viability and germ tube formation of Candida albicans, with a proposed cAMP-linked mechanism. Charnley et al. (2008) reported antibacterial activity for α-MSH, Ac-Lys-Pro-Val-NH₂ and Ac-Lys-Pro-D-Val-NH₂ against S. aureus and E. coli, and found the cationic lysine charge was not required for it.

Against that, Songok et al. (2018) reported no antimicrobial activity for Ac-KPV-NH₂ or its glycoalkylated analogs across a range of assay conditions. The honest summary: activity has been reported in several studies, appears assay- and analog-dependent, and at least one published attempt failed to reproduce it.

Why KPV is discussed alongside BPC-157

KPV frequently appears next to BPC-157 in research-material catalogs and blended preparations. The association is thematic rather than experimental: both are short peptides whose preclinical literature centers on gastrointestinal and tissue-repair models, and both interest the same investigators.

What the published record does not contain is controlled study of the combination. A literature search returns no primary preclinical work evaluating KPV and BPC-157 together against either compound alone — no comparative data, no basis for claims of additive or synergistic effects, and no characterization of how the two behave in a shared solution. Their mechanistic literatures are also distinct, so complementarity is an inference rather than a finding. Any work involving both is uncharacterized territory.

Handling and stability in a laboratory context

KPV is typically supplied as a lyophilized powder. The points below reflect general peptide-handling practice and observations from the formulation literature; they concern material integrity only.

• Proteolytic susceptibility. Short unprotected peptides are readily degraded by peptidases. Songok et al. modified KPV structurally to address enzymatic degradation and rapid elimination, reporting that glycoalkylated analogs showed improved stability toward proteolytic enzymes — an indication of the native tripeptide's vulnerability in biological matrices.
• Solution state is the vulnerable one. Zhao et al. (2022) noted that KPV bound within their hydrogel retained bioactivity longer at 50 °C than free peptide. As in peptide chemistry generally, the dry lyophilized form is the stable one; in solution, stability depends on temperature, pH and time.
• Analog identity matters. Free KPV, Ac-KPV-NH₂, H-KPV-NH₂ and the D-Val variant are different compounds with different reported behavior. Results should be compared only against studies using the same form.
• Documentation. Purity data, mass spectrometry confirmation and lot records are what make any experimental result interpretable.

Limitations of the evidence

The single most important fact about KPV is the shape of its evidence base.

• The evidence is preclinical. The findings above come from cultured cell lines, mice, rats and rabbits. Nothing in that work establishes what happens in humans.
• Human clinical data is minimal to absent. A search of registered clinical trials returns no interventional studies of KPV: no published Phase I, II or III program, no human efficacy data, no human safety characterization.
• Delivery is an unsolved problem. The share of the literature devoted to nanoparticles, hydrogels and film dressings is itself evidence that free KPV is poorly retained and rapidly cleared. Results from an engineered delivery system do not transfer to the free peptide.
• Findings are model-specific. DSS and TNBS colitis are chemically induced injury models — standard research tools, not equivalents of human inflammatory bowel disease.
• Some findings conflict. The antimicrobial literature is the clearest example, with a published negative result standing against earlier positive ones.
• The mechanism is incompletely resolved. Receptor-independence is well supported, but the intracellular target remains a set of competing proposals — IL-1β interference, importin-α/p65RelA blockade, PepT1-dependent accumulation — rather than one established mechanism.

Secondary sources routinely compress all of this into confident statements about what KPV does for inflammation, gut health or skin. The primary literature does not support them; it describes effects in defined experimental systems and says little else.

Reference note

This article is research-use-only reference material for laboratory and educational contexts. It describes published preclinical findings and is not medical advice, not a description of therapeutic use, and not a basis for any human application. KPV is not an approved drug in any jurisdiction, and no compound discussed here is intended for human or veterinary use, diagnosis, treatment or consumption.

References

• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026
• Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Böhm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. doi:10.1002/ibd.20334
• Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631–637. doi:10.1124/jpet.103.051623
• Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012;4(2):59–73. PMID: 22837805
• Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology. 2016;2(3):340–357. doi:10.1016/j.jcmgh.2016.01.006
• Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853. doi:10.1053/j.gastro.2009.11.003
• Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628–1640. doi:10.1016/j.ymthe.2016.11.020
• Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, Ran K, Zhuge D, Yao Q, Xu H. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomaterialia. 2022;143:233–252. doi:10.1016/j.actbio.2022.02.039
• Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233–239. doi:10.1002/jlb.67.2.233
• Charnley M, Moir AJ, Douglas CW, Haycock JW. Anti-microbial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence in Gram-positive and Gram-negative bacteria. Peptides. 2008;29(6):1004–1009. doi:10.1016/j.peptides.2008.02.004
• Songok AC, Panta P, Doerrler WT, Macnaughtan MA, Taylor CM. Structural modification of the tripeptide KPV by reductive “glycoalkylation” of the lysine residue. PLoS ONE. 2018;13(6):e0199686. doi:10.1371/journal.pone.0199686
• Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11–13) on corneal epithelial wound healing: role of nitric oxide. Experimental Eye Research. 2006;83(6):1366–1372. doi:10.1016/j.exer.2006.07.014
• Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology. 2019;28(3):219–224. doi:10.1111/exd.13887
• Shao W, Chen R, Lin G, Ran K, Zhang Y, Yang J, Pan H, Shangguan J, Zhao Y, Xu H. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomaterials Science. 2021;10(1):227–242. doi:10.1039/d1bm01466h
• Zhao Y, Huang L, Lin G, Tong M, Xie Y, Pan H, Shangguan J, Yao Q, Xu S, Xu H. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. International Journal of Biological Macromolecules. 2022;222(Pt B):2729–2743. doi:10.1016/j.ijbiomac.2022.10.054